基于循证医学证据的多方优势，泽布替尼有望成为中国CLL患者的安心之选( 三 ) 慢性淋巴细胞性白血病（CLL）是一类以

文章插图
图4：SEQUOIA研究疗效数据更新[12]
总结
我国自主研发的新一代BTK抑制剂泽布替尼在中国上市，为中国淋巴瘤的治疗开创了新的局面。泽布替尼的研发及其在淋巴瘤治疗领域的突破是我国本土生物医药行业和临床肿瘤研究的一个重要里程碑，标志着我们不仅能为中国患者研发新药，也能让更多国家的患者受益其中，为世界提供中国的方案，贡献中国的智慧。现阶段，泽布替尼单药及联合治疗在淋巴瘤多个治疗领域的研究均在布局中，期待其能够多点开花，不断扩展临床适应证，为更多患者带来生命曙光，引领未来淋巴瘤的治疗方向，也期待泽布替尼能够纳入医保调整目录，提高药物可及性，惠及更多中国淋巴瘤患者！
参考文献：
1.程诗佳等. 慢性淋巴细胞白血病治疗进展. 白血病·淋巴瘤, 2020, 6(29), 381-384.
2.NCCN Clinical Practice Guidelines in Oncology for CLL/SLL. V4.2020.
3.2020 CSCO淋巴瘤诊疗指南.
4.Bruno Emond, et al. Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy. Clinical Lymphoma, Myeloma 24:1219-1228.
6.Catherine Waweru, et al. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. ISSN:0300-7995(Print)1473-4877(Online).
7.Presented at the 14th International Conference on Malignant Lymphoma; Jun 14?17, 2017; Lugano, Switzerland.
8.Pal Singh S, et al. Mol Cancer 2018;17(1):57.
9.Li N, et al. Cancer 2015;75:2597.
10.Xu W, et al.Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.Journal of Hematology & Oncology (2020) 13:48.
11.Cull G, et al. 61st ASH Annual Meeting (2019). Abstract No:500.
12.
13.